442 related articles for article (PubMed ID: 18006836)
1. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
2. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
3. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
4. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kazhdan I; Marciniak RA
Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.
Zhang L; Gu J; Lin T; Huang X; Roth JA; Fang B
Gene Ther; 2002 Sep; 9(18):1262-70. PubMed ID: 12215894
[TBL] [Abstract][Full Text] [Related]
6. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
[TBL] [Abstract][Full Text] [Related]
7. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
[TBL] [Abstract][Full Text] [Related]
8. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
9. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
[TBL] [Abstract][Full Text] [Related]
10. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance.
Sivaprasad U; Shankar E; Basu A
Cell Death Differ; 2007 Apr; 14(4):851-60. PubMed ID: 17186022
[TBL] [Abstract][Full Text] [Related]
12. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
[TBL] [Abstract][Full Text] [Related]
14. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
15. [Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer].
Zhu HB; Huang XF; Hu JZ; Zhou W; Chen W; Chen LL; He C
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):245-9. PubMed ID: 18788624
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
17. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
18. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
[TBL] [Abstract][Full Text] [Related]
19. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
[TBL] [Abstract][Full Text] [Related]
20. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
